A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19

By sjmartinez • November 26, 2024

Seethamraju H, Yang OO, Loftus R, Ogbuagu O, Sammartino D, Mansour A, Sacha JB, Ojha S, Hansen SG, Arman AC, Lalezari JP. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19. Clin Ther. 2024 Nov;46(11):891-899. doi: 10.1016/j.clinthera.2024.08.019. Epub 2024 Sep 30. PMID: 39353749.

Tags: covid-19, Infectious Diseases, leronlimab, NEWS2, Publications, Randomized placebo-controlled trial, SARS-CoV-2

Rapid and comprehensive detection of viral antibodies and nucleic acids via an acoustofluidic integrated molecular diagnostics chip: AIMDx

Qian J, Xia J, Chiang S, Liu JF, Li K, Li F, Wei F, Aziz M, Kim Y, Go V, Morizio J, Zhong R, He[...]

Mpox primer for clinicians: what makes the difference in 2024?

Abdel-Rahman SM, Bayıcı BZ, Keske Ş, Kuşkucu M, Özsürekçi Y, Rimoin AW, Rodriguez-Morales AJ, Ergönül Ö. Mpox primer for clinicians: what makes the difference in[...]

Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients

Pickering H, Schaenman J, Phan HV, Maguire C, Tsitsiklis A, Rouphael N, Higuita NIA, Atkinson MA, Brakenridge S, Fung M, Messer W; IMPACC Network; Salehi-Rad[...]